Effective Treatment of Vaginal Atrophy With an Ultra–Low-Dose Estradiol Vaginal Tablet
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the efficacy of ultra-low-dose 10-microgram 17beta-estradiol (E2) vaginal tablets for treatment of vaginal atrophy. METHODS: Postmenopausal women (N=309) were randomly assigned to 10-microgram E2 or placebo vaginal tablets for 52 weeks in a multicenter, double-blind study. Primary efficacy endpoints included change from baseline to week 12 in vaginal cytology, vaginal pH, and most bothersome urogenital symptoms score. Grading of vaginal health was a secondary efficacy assessment. Safety assessments included endometrial biopsy, physical and gynecologic examinations, and recording adverse events. RESULTS: At week 12, the change from baseline for 10 micrograms E2 compared with placebo demonstrated significant improvement in vaginal Maturation Index (proportion of parabasal cells: -37% compared with -9%; superficial cells: 13% compared with 4%; intermediate cells: 24% compared with 5%; P<.001 for each), Maturation Value (25.0 compared with 6.5, P<.001), grading of vaginal health (-0.91 compared with -0.51, P<.001), vaginal pH grade (-1.3 compared with -0.4, P<.001), and most bothersome symptoms score (-1.23 compared with -0.87, P=.003). For each component of vaginal Maturation Index, vaginal Maturation Value, grading of vaginal health, and vaginal pH, treatment effects were statistically different from placebo after 2 weeks of treatment. For most bothersome symptoms, treatment effect became apparent after 4 weeks and reached statistical significance at week 8 of therapy. All treatment effects were statistically significant at week 52. There were no major safety findings regarding physical, gynecologic, or laboratory assessments. CONCLUSION: After 12 weeks of treatment, an ultra-low-dose 10-microgram E2 vaginal tablet, compared with placebo, demonstrated significant improvement for the primary endpoints: vaginal cytology and pH and most bothersome urogenital symptoms score. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT00108849 LEVEL OF EVIDENCE: I.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CARDOZO, L. (1998) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(98)00175-6 · Cited by 388
Cited by
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
Self-citationLocal oestrogen for vaginal atrophy in postmenopausal women
Lethaby, A., Ayeleke, R. O., & Roberts, H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001500.pub3 · Cited by 601
(2013) · Menopause · doi:10.1097/gme.0b013e3182a122c2 · Cited by 560
(2020) · Menopause · doi:10.1097/gme.0000000000001609 · Cited by 531
Mac Bride, M. B., Rhodes, D. J., & Shuster, L. T. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0413 · Cited by 444
RETRACTED: Practice Bulletin No. 141 Management of Menopausal Symptoms
(2014) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000441353.20693.78 · Cited by 434
RetractedVaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey
Nappi, R. E., & Kokot-Kierepa, M. (2012) · Climacteric · doi:10.3109/13697137.2011.647840 · Cited by 407
Vaginal Estrogen for Genitourinary Syndrome of Menopause: A Systematic Review
Rahn, D. D., Carberry, C., Sanses, T. V., Mamik, M. M., Ward, R. M., Meriwether, K. V., Olivera, C. K., Abed, H., Balk, E. M., & Murphy, M. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000526 · Cited by 309
Martel, C., Labrie, F., Archer, D. F., Ke, Y., Gonthier, R., Simard, J.-N., Lavoie, L., Vaillancourt, M., Montesino, M., Balser, J., et al. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.016 · Cited by 72
Self-citationInterpersonal trauma and aging-related genitourinary dysfunction in a national sample of older women
Gibson, C. J., Lisha, N. E., Walter, L. C., & Huang, A. J. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.09.026 · Cited by 18
Metadata
- Authors
- Simon, J., Nachtigall, L., Gut, R., Lang, E., Archer, D. F., & Utian, W.
- Venue
- Obstetrics & Gynecology
- Published
- 2008-11
- Volume
- 112
- Issue
- 5
- Pages
- 1053-1060
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2100392631
- Cited by
- 155
- References
- 1
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.